NCT00654589View on ClinicalTrials.gov

Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Iron Overload
Interventions
DRUG

Deferasirox

Trial Locations (1)

Unknown

Novartis Investigative Site, Leipzig

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00654589 - Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload | Biotech Hunter | Biotech Hunter